86 yrs male.
HISTORY: EPISODE 1: In 2017 November resected caecum adenocarcinoma (mucinous, G2, pT3 N0(26). Microasatelitte stable/no MS protein loss. Molecs not performed. Incidental non-metastatic nodes were detected: DLBCL + Mantle cell lymphoma (predominant mantle pattern; conventional cytology). IH MCL: CD20+; CD5+; Cyclin D1+. DLBCL (GCB; heterogenous)(1 node): CD20+; CD10+/bcl6+; Cyclin D1+; CD5(-); cMYC(-); MUM1+; Ki67 proliferacinis aktyvumas iki 95%. CLONALITY: 2 clonally unralated profiles: IGH locuses FR1-3, D-J and IGK V/JC-Kde. IGL, TCRB, TCRG ir TCRD polyclonal. FISH: DLBCL: No CCND1 (11q13) and MYC (8q24) break. MYC/IGH CEP8 fusion absent too. MCL: CCND1 (11q13) break in mantle zones. EPISODE 2: 2018 February: Threpine biopsy/staging: reactive changes (IH for lymphoma only). NO THERAPY APPLIED! EPISODE 3: 2019 February threpine biopsy: Panyperplasia with architectural damage, erythroid hyperplasia/dysplasia, megakariopoietic hyperplasia/dysplasia (CD7/CD34+), CD34+ blast count up to 5%, reticulin fibrosis MF1: high grade MDS with multilineal dysplasia and sideroblasts (MDS-MD-RS-F). Complex karyotype (SNP): Dels 5q, 7q, 12p, 16q, 17p and trisomy 8. DIAGNOSTIC QUESTION: 1. CRC+ 3 different clonal diseases. Fragile genome? 2. Clinically "silent" DLBCL+ MCL without treatment for 2 yrs. 3. No clonal or IH relationships between CD5+ CyclinD1+ MCL and CyclinD1+ DLBCL (GCB). 4. HETEROGENEITY and BLASTOID appearance of DLBCL.
Gallery:
Annotations
»
Add comment
(Login)
|
Last modified: 2019-04-04 15:33:07